Compare American Superconductor Corporation (AMSC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Merck & Co., Inc. — how do they compare? American Superconductor Corporation trades at $33.08 (market cap $1.56B), while Merck & Co., Inc. trades at $131.78 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 206.3× American Superconductor Corporation's market cap, and Merck & Co., Inc. pays a 2.61% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | MRK | |
|---|---|---|
Market Cap | $1.56B | $321.77B |
Sector | Technology | Health |
52-Week High | $66.68 | $131.84 |
52-Week Low | $25.95 | $77.60 |
Enterprise Value | $1.42B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $33.19, up 7.1% today, showing strong momentum despite a bearish technical signal. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Analyst consensus leans bullish with 53% buy ratings, while technical indicators show resistance at $34 and support at $30.
Outlook remains mixed with strong revenue growth and record backlog providing visibility, but margin compression and aggressive valuation pose risks. The stock offers growth potential in energy infrastructure markets, though investors should monitor execution on profitability targets amid increasing competition.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
